March 1st 2024
Obesity rates in the US over the 3 decades rose from 11.5% to 21.7% among boys and from 11.6% to 19.4% among girls. US men ranked 10th highest for obesity in 2022.
February 28th 2024
Analysis of heart registry data for SELECT trial-eligible adults (obesity, first MI, no diabetes) found an NNT of 49 and 5-year MACE incidence of 10.7%.
Viking's VENTURE trial met primary and all secondary endpoints, with GI-related TAEAs reported as mild/moderate and diminishing over the course of the 13-week study.
February 27th 2024
The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.
February 23rd 2024
Your daily dose of the clinical news you may have missed.
PCOS Ups Risk of Maternal, but Not Neonatal Adverse Outcomes in Women with T2D in Pregnancy
Women with PCOS and T2D in pregnancy were at greater risk for high insulin requirements, excess weight gain, and worsening of pregestation hypertension if treated with metformin.
Rise in GLP-1 Mimetic Demand Will Continue as Pluripotency Expands
The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?
Evening Chronotype in Women Linked with Unhealthy Lifestyle, Increased Risk for Type 2 Diabetes
Women with an evening vs morning chronotype were 54% more likely to have unhealthy lifestyles that in turn accounted for a significant increased risk for diabetes.
Biden Administration Announces First 10 Prescription Drugs Slated for Price Negotiations
The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.
Daily Dose: Semaglutide May Benefit 93 Million US Adults
A daily dose of clinical news on Patient Care you may have missed.
Cardiorenal Risk Estimates in T2D Mediated by Common Biomarker Response to Canagliflozin
Reduction in levels of 4 biomarkers was correlated with lower risk of composite cardiorenal outcomes in the CREDENCE trial, suggesting use of the panel to augment current risk assessment tools.
Daily Dose: Effect of Sotagliflozin on Heart Failure-Related Events
Semaglutide 2.4 mg Could Reduce US Obesity by Half, Prevent 1.5 million CVD Events
More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.
NIH Designates Centers of Excellence to Improve Maternal Health Equity
The newly named centers across the country will work closely with communities to focus research on populations at greatest risk for perinatal morbidity and mortality.
Daily Dose: Daily Sugared Drink Intake & Risk of Hepatic Morbidity, Mortality in Postmenopausal Women
Amazon Pharmacy Announces Insulin Discounts with Automatic, Manufacturer-sponsored Coupons
Patients with diabetes will be able to save money when ordering insulin and commonly prescribed products, such as continuous glucose monitors and pumps.
Sotagliflozin Cut Risk by >50% for HF Rehospitalization and CV Death when Started Before Discharge
A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.
Daily Dose: Diabetes- and CVD-Related Death Increase After 10-Year Decline
Daily Dose: Vegetarian Diet Boosts Optimal Drug Therapy in High-Risk CVD Patients
Insulin Prescription Fills Up Following Inflation Reduction Act Cap on Out-of-Pocket Costs
The new policy is helping people who are taking insulin save money and helping others to afford it in the first place, says a study coauthor from the USC Sol Price School of Public Policy .
Mean Weight Loss with Tirzepatide Reaches 26% Across 2 Pivotal Phase 3 Clinical Trials
In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.
Vegetarian Diet May Augment Effects of Optimal Drug Therapy in Patients at High Risk of CVD
Reductions in LDL-C, HbA1c, and body weight were associated with a variety of vegetarian diets in participants with or at high risk for cardiovascular disease.
Social Determinants of Health and Prevention of Cardiovascular Disease
Methods proven to prevent ASCVD may fall short in certain populations if the impacts of SDOH are not closely monitored. The ACC/AHA provide considerations for 7 health domains.
Diabetes- and CVD-Related Mortality Rise after Steady 10-Year Decline
Since 2014, the age-adjusted mortality rate for diabetes and CVD has increased by 1% after an overall decline between 1999 and 2019, new research finds.
When Statin Guidelines Collide: 5 Questions on 2 Approaches to Primary CVD Prevention
Guidelines on primary ASCVD prevention from the USPSTF and the AHA/ACC/Multisociety differ on why and when to initiate a statin. Try the 5-question quiz.
Daily Dose: The BMI vs Body Fat Debate
Your daily dose of clinical news you may have missed.
Prescription Digital Behavioral Therapeutic for Type 2 Diabetes Wins FDA Marketing Clearance
AspyreRx™, prescribed in 90-day increments, resulted in a mean HbA1c reduction of 1.3% at 180 days in 1 out of 2 phase 3 trial participants. A Q4 launch is anticipated.
Daily Dose: T2D Raises Risk for Hepatic Decompensation, Hepatocellular Carcinoma in Patients with NAFLD
BMI vs body fat; menopause and martinis; statin guidelines collide; +2 - The Five for Friday
Is BMI or body fat a better estimate of obesity?; spoiler: older women do drink ETOH; USPSTF vs ACC/AHA; plus no more opioids for LBP and a primer on migraine meds.
The BMI vs Body Fat Debate: Study Suggests One-Third of People with Normal BMI are Obese
In Israel, where 60% of adults are overweight, new research prompts investigators to suggest that % body fat should replace BMI as the gold standard measure of obesity.
Menopause and ETOH: Beware the Tipping Point
Binge drinking among women going through menopause has been on the rise, research indicates, making clinical inquiry in this population particularly important.
In Patients with NAFLD, Type 2 Diabetes Significantly Ups Risk for Hepatic Decompensation, Hepatocellular Carcinoma
In patients with NAFLD, type 2 diabetes was found to be an independent predictor of both hepatic decompensation and incident HCC, according to meta-analysis authors. .
Expert to Primary Care: Use these "ABCs" to Manage Obesity and T2D
The importance of avoiding judgement, monitoring behavior, and cardiovascular risk prevention in primary care are discussed, here.
Inclisiran Label Expanded to Include Primary Prevention Population
The expanded indication widens the patient population eligible for the novel siRNA therapy to include high-risk patients on maximum statin Rx who have not had a CV event.
Statins Appear Beneficial for CV Outcomes in Primary Prevention Patients with HTN without CVD or Diabetes
In a study of over 26 000 participants, statin use was associated with reduced risk for all-cause and CV mortality compared to placebo.
2 Commerce Drive Cranbury, NJ 08512